The European Union H2020 programme has awarded a €15 million grant to the Ubiquitous Pharmacogenomics (U-PGx) consortium for an international pharmacogenomics research and implementation project.
The aim of the U-PGx consortium is to make actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen. The objective of the research and implementation project is to map genetic profiles of 8,000 patients, and then implement stratified prescribing of drugs in these patients based on the Dutch Pharmacogenetics Working Group guidelines. The cost-effectiveness and clinical-effectiveness of this approach will then be evaluated. Educational activities are also planned to assist in the training and education of health care professionals and patients regarding pharmacogenomics.
U-PGx will host its 1st annual consortium meeting in Athens, Greece in September 2016; Teri Klein, co-principal investigator of PharmGKB and the Clinical Pharmacogenetics Implementation Consortium (CPIC), will be in attendance. Dr. Russ Altman, co-principal investigator of PharmGKB, is on the advisory board for U-PGx.
Visit the U-PGx website